

Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

ChemDiv

RRID:SCR_027402

Type: Tool

Proper Citation

ChemDiv (RRID:SCR_027402)

Resource Information

URL: <https://www.chemdiv.com/>

Proper Citation: ChemDiv (RRID:SCR_027402)

Description: Target-to-Clinic Contract Research Organization (CRO) headquartered in San Diego, CA USA. ChemDiv executes pre-clinical discovery chemistry and biology for drug development and clinical trials for international portfolio of companies across the entire range of targets with small molecule and biotech drugs. The company operates multiple research and development (R&D) subsidiaries in Russia, Ukraine and China as well as business operations around the world.

Resource Type: commercial organization

Keywords: drug development, small molecule, biotech drugs,

Resource Name: ChemDiv

Resource ID: SCR_027402

Record Creation Time: 20250905T055005+0000

Record Last Update: 20260808T190812+0000

Ratings and Alerts

No rating or validation information has been found for ChemDiv.

No alerts have been found for ChemDiv.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Jiang X, et al. (2026) AI-Driven Acceleration of Fluorescence Probe Discovery. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(10), e15604.

Yin P, et al. (2026) Identification and characterization of novel chikungunya virus polymerase inhibitors. *Journal of virology*, 100(6), e0030526.

Tseng HJ, et al. (2026) Identification and biological evaluation of benzimidazole-based compounds as novel TGF β 1 inhibitors. *Journal of enzyme inhibition and medicinal chemistry*, 41(1), 2600746.

Pal S, et al. (2026) Deciphering the Structural Basis of Allosteric Inhibition of Mutant Epidermal Growth Factor Receptor and Identification of Novel Inhibitors. *Computational and structural biotechnology journal*, 35(1), 0118.

Qi C, et al. (2025) Discovery of Potential Scaffolds for Methionine Adenosyltransferase 2A (MAT2A) Inhibitors: Virtual Screening, Synthesis, and Biological Evaluation. *Molecules* (Basel, Switzerland), 30(10).

Zhu Z, et al. (2025) Identification of a Selective Inhibitor of Human NFS1, a Cysteine Desulfurase Involved in Fe-S Cluster Assembly, via Structure-Based Virtual Screening. *International journal of molecular sciences*, 26(6).

Guo CR, et al. (2025) Understanding interspecies drug response variations between human and rodent P2X7 receptors. *Nature communications*, 16(1), 10827.

Easton V, et al. (2025) Discovery of three small-molecule inhibitors targeting Ebolavirus genome replication and transcription. *The Journal of general virology*, 106(12).

Wang S, et al. (2025) Discovery of N-(2-Acetamidobenzo[d]thiazol-6-yl)-2-phenoxyacetamide Derivatives as Novel Potential BCR-ABL1 Inhibitors Through Structure-Based Virtual Screening. *Molecules* (Basel, Switzerland), 30(5).

Wu K, et al. (2025) TransMA: an explainable multi-modal deep learning model for predicting properties of ionizable lipid nanoparticles in mRNA delivery. *Briefings in bioinformatics*, 26(3).

Wu K, et al. (2024) Data-balanced transformer for accelerated ionizable lipid nanoparticles screening in mRNA delivery. *Briefings in bioinformatics*, 25(3).

Chen X, et al. (2024) Phase separation of Nur77 mediates XS561-induced apoptosis by promoting the formation of Nur77/Bcl-2 condensates. *Acta pharmaceutica Sinica. B*, 14(3), 1204.

Hasnat S, et al. (2024) Pantothenate kinase: A promising therapeutic target against pathogenic *Clostridium* species. *Heliyon*, 10(14), e34544.

Lin TE, et al. (2024) An ensemble machine learning model generates a focused screening library for the identification of CDK8 inhibitors. *Protein science : a publication of the Protein Society*, 33(6), e5007.

Massudi H, et al. (2023) Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface. *Cancers*, 15(6).

Babu S, et al. (2022) Identification of Potent and Selective JAK1 Lead Compounds Through Ligand-Based Drug Design Approaches. *Frontiers in pharmacology*, 13, 837369.

Shishido H, et al. (2022) A small molecule high throughput screening platform to profile conformational properties of nascent, ribosome-bound proteins. *Scientific reports*, 12(1), 2509.

Wang L, et al. (2022) Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen. *European journal of medicinal chemistry*, 244, 114803.

Nabati F, et al. (2022) Virtual screening based on the structure of more than 105 compounds against four key proteins of SARS-CoV-2: MPro, SRBD, RdRp, and PLpro. *Informatics in medicine unlocked*, 35, 101134.

Zhang C, et al. (2021) Discovery of SIRT7 Inhibitor as New Therapeutic Options Against Liver Cancer. *Frontiers in cell and developmental biology*, 9, 813233.